Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064363 · ClinicalTrials.gov registry record · Phase 2
Talampanel in Treating Patients With Recurrent High-Grade Glioma
A Phase 2 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00064363 is a Phase 2 study that has completed, run by National Institutes of Health Clinical Center (CC).
The verdict
NCT00064363, a Phase 2 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy such as talampanel use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well talampanel works in treating patients with recurrent, progressive high-grade glioma.
Interventions
- DRUG talampanel
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-06 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00064363
The ClinicalTrials.gov registry entry for NCT00064363 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which talampanel is the first listed.
NCT00064363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00064363 about?
NCT00064363 is a clinical study titled "Talampanel in Treating Patients With Recurrent High-Grade Glioma". RATIONALE: Drugs used in chemotherapy such as talampanel use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well talampanel works in treating patients with recurrent, progressive high-grade glioma.
What is the current status of trial NCT00064363?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-06. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00064363?
The interventions under investigation include: talampanel (DRUG).
Who is sponsoring clinical trial NCT00064363?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.